Detection of HSV Type-2, CMV and Adenovirus lgG Antibodies in Patients with Hematologic and Solid Organ Malignancies
Abstract views: 55
/ 
PDF downloads: 57
DOI:
https://doi.org/10.58600/eurjther.1995-6-2-1521-archKeywords:
Malignancy, HSV-2, CMV, AdenovirusAbstract
The presence of Herpes Simplex Virus-type 2 (HSV type 2), Cytomegalovirus(CMV) and Adenovirus lgG antibodies was determined in sera from a total of 144 patients with hematologic and solid organ malignancies. HSV type-2 antibodies were detected using the EIA method and antibody levels were detected in 34(48.5 %) ofthe hematologic and in 56(75.6 %) ofthe solid organ malignancies with a total of90 (62.5 %). Anti-CMV IgG antibodies were detected in the same serum samples using the complement fixation test. Residual anti-CMV antibody levels were detected in 43(61.4) ofhematologic and 39 (52.7 %) ofsolid organ malignancies with a total of82 (56.9 %) serum samples.
Adenovinıs antibodies were detected using the complement fixation test. Residual antibodies were found in 51(72.8 %) of hematologic and in 33(44.5 %) of solid organ malignancies cut of a total of 84(58.3 %).
Metrics
References
Akan E:Genel ve özel Viroloji, Türkiye Klinikleri Yayınevi, 2.Baskı. Ankara, 1989.
Awidi AS:Infections in adults with cancer in a developing country, a three year prospective study. Eur J Cancer 27:4, 423-426, 1991.
Feld R:The Comproınised host. Eur J Cancer Clin Oncol 25: 1-7, 1989.
Pizzo PA:Evaluation of fever in the patient with cancer. Eur J Cancer Clin Oncol 25:9-16, 1989.
Pizz.o PA, Young RC:lnfections in the cancer patient. Devita VI, Helman S, Rosenberg SA:Cancer. Principles and Practice ofüncology.(2 nd ed.) 1985, p: 1964-1968.
Schimpff SC:Infections in the compromised host.ln:Mandell GS, Douglas RG, Jr Bennett JE:Principles and Practice of Infectious Diseases. New York, John Wiley and Sons, 1990, p:2258-2266.
Moossa AR, Robson MC, Schimpff SC:lnfections in patients with cancer. in:Comprehensive Textbook of Oncology. 1986, p:367-377.
Pizzo PA, Commers J, Cotton D,et al:Approacrung the Controversies in Antibacterial Management of Cancer Patients. Am J Med 76:436-437, 1984.
Jones PG, Rolston KVI, Fainstein V, et al:Aztreonam Therapy in Neutropenic Patients with Cancer. Am Med 81 :243-248, 1986.
Hersman J, Meyers JD, Thomas ED:The etfect of granulocyte transfusions on the incidence of cytomegalovirus infections after allogenic marrow transplantation. Ann hıtern Med 96: 149- 152, 1982.
Joshi JH, Schımptf SC, Tenney JH. et al:Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients. Am J Med 76:450, 1984.
Meyers JD, McGuffın RW, Neiman PE, et al:Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J hıfectt Dis 141:555-562, 1980.
Pechere JC:Emergence of resistance in gram-negative bacilli during P-lactam therapy:a challenge for the future. Eur J Cancer Clin Oncol 25: 17-23, 1989.
K.lastersky J:hıfections in Comprimised Hosts:Cociderations on Prevention. Eur J Cancer Clin Oncol 25:53--01, 1989.
Wong KK, Hırsch MS:Herpes virus infections in patients with neopastic disease. Am J Med 76:464-478, 1984.
Zahradnik JM, Spencer MJ, Porter DD:Adenovirus infections in the immunocompromised patient. Am J Med 68:725-732, 1980.
Whitley RE, Whelchel J, Dietheim AG, et al:Infections caused by Herpes simplex virus in the immunocompromised host. J Infect Dis 150-3, 1984.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
